<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>1 </plain></SENT>
<SENT sid="1" pm="."><plain>Changes in the peripheral type <z:chebi fb="13" ids="22720">benzodiazepine</z:chebi> binding site density following middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in the mouse, have been used as a marker of neuronal damage </plain></SENT>
<SENT sid="2" pm="."><plain>These sites can be identified using the selective ligand [3H]-PK 11195 located on non neuronal cells, macrophages and astroglia, within the <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Glial cell proliferation and macrophage invasion is an unvoidable sequelae to cerebral ischaemic injury, secondary to <z:hpo ids='HP_0002529'>neuronal loss</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Following occlusion of the left middle cerebral artery (left <z:chebi fb="70" ids="34342">MCA</z:chebi>) a reproducible lesion was found in the parietal cortex within 7 days which gave rise to a significant increase in [3H]-PK 11195 binding </plain></SENT>
<SENT sid="5" pm="."><plain>2 </plain></SENT>
<SENT sid="6" pm="."><plain>Treatment of animals with the <z:chebi fb="199" ids="26708">sodium</z:chebi> channel blocker, lifarizine, significantly reduced the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced increase in [3H]-PK 11195 binding when given either 30 min pre-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> and three times daily for 7 days at 0.5 mg kg-1, i.p </plain></SENT>
<SENT sid="7" pm="."><plain>(P &lt; 0.01) or delayed until 15 min post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> and three times daily for 7 days at 0.5 mg kg-1, i.p </plain></SENT>
<SENT sid="8" pm="."><plain>(P &lt; 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>Lifarizine was an effective neuroprotective agent in this model of focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> in the mouse </plain></SENT>
<SENT sid="10" pm="."><plain>3 </plain></SENT>
<SENT sid="11" pm="."><plain>Lifarizine also showed a dose-related protection against the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced increase in [3H]-PK 11195 binding with significant protection at doses of 0.1 mg kg-1, i.p </plain></SENT>
<SENT sid="12" pm="."><plain>(P &lt; 0.05), 0.25 mg kg-1, i.p </plain></SENT>
<SENT sid="13" pm="."><plain>(P &lt; 0.01) or 0.5 mg kg-1, i.p </plain></SENT>
<SENT sid="14" pm="."><plain>(P &lt; 0.01) 15 min post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> and b.i.d. for 7 days </plain></SENT>
<SENT sid="15" pm="."><plain>No significant change is seen in the Kd for [3H]-PK 11195 </plain></SENT>
<SENT sid="16" pm="."><plain>The first dose could be delayed for up to 4 h after cerebralartery cauterization and protection was maintained.4 </plain></SENT>
<SENT sid="17" pm="."><plain>Phenytoin (28 mg kg-1, i.v </plain></SENT>
<SENT sid="18" pm="."><plain>15 min and 24 h post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>) was also neuroprotective in this model(P&lt;0.01) </plain></SENT>
<SENT sid="19" pm="."><plain>This agent is thought to interact with voltage-dependent <z:chebi fb="199" ids="26708">sodium</z:chebi> channels to effect its anticonvulsantactions and this mechanism may also underlie its neuroprotective actions in focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebralischaemia</z:e>.5 </plain></SENT>
<SENT sid="20" pm="."><plain>Agents with other mechanisms of action were also shown to have significant neuroprotection in this model </plain></SENT>
<SENT sid="21" pm="."><plain>The non-competitive <z:chebi fb="0" ids="31882">NMDA</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi>, MK 801, showed significant neuroprotection in the model when given at 0.5 mg kg-1, i.p </plain></SENT>
<SENT sid="22" pm="."><plain>30 min pre-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> with t.i.d. dosing for 7 days (P&lt; 0.001) </plain></SENT>
<SENT sid="23" pm="."><plain>The <z:chebi fb="0" ids="50075">dihydropyridine</z:chebi> calcium <z:chebi fb="68" ids="48706">antagonist</z:chebi>, nimodipine was not protective when given using the same dosing protocol as MK 801, 0.5 mg kg-1 30 min pre-occlusion and three times daily for 7 days but showed significant protection when given at 0.05 mg kg-1 15 min post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> and three times daily for 7days </plain></SENT>
<SENT sid="24" pm="."><plain>The <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation inhibitor, tirilazad (single dose 1 mg kg-1, i.v.) showed significant neuroprotection when given 5 min post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> but not when the first dose was delayed for 4 h </plain></SENT>
</text></document>